To view this email as a web page, click here.

It's your business
 
Abatacept: Pricey, but Effective
The approval of abatacept (Orencia/Bristol-Myers Squibb) for psoriatic arthritis (PsA) earlier this month by the FDA offers a new treatment option for patients who are struggling to keep the disease under control.
Learn more.
ADVERTISEMENT
 
Blindspots to success
According to one expert, many cosmetic practices are competing on price because aesthetic physicians don't know how to market in an age of "experience marketing."
Learn more.
ADVERTISEMENT
 
In case you missed it
 
Atopic dermatitis comorbidities
Emerging data suggest that atopic dermatitis is not just a skin disease. In terms of its impact on the whole patient and its potential for multi-organ involvement, it is a systemic disease, according to one dermatologist.
Learn more.
 
JOB OPPORTUNITIES
 
 
ADVERTISEMENT
Is your tech saving your practice money?
In the new world of value-based care, technology matters. This whitepaper plugs you into Cloud-based solutions that can help improve clinical outcomes — and transform healthcare IT from a distraction into an advantage. Read the whitepaper now. »
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.